- Stoke Therapeutics Inc STOK announced data from a planned interim analysis of the ongoing Phase 1/2a MONARCH and ADMIRAL clinical studies of STK-001 in children and adolescents with Dravet syndrome.
- Today's results come almost a year after Stoke touted its first-in-human data for STK-001.
- In addition to positive safety, pharmacokinetic (PK) and cerebrospinal fluid (CSF) exposure data, median reductions in seizure frequency were observed among patients who were treated with multiple doses of STK-001 (20mg, 30mg and 45mg).
- In a subgroup of six patients examined at the highest dose (45mg) so far — who had all received three doses — Stoke observed a median 55% reduction in convulsive seizure frequency.
- The reduction was seen between four weeks after patients received their first 45 mg dose and three months after receiving their third dose. They were among a total of 55 patients who had received at least one drug dose at any level.
- The 20 and 30 mg doses performed numerically worse than the 45 mg in Monday’s data cut. In four patients who took three 20 mg doses, Stoke saw a median 41% reduction from baseline, while in 17 patients at the three-dose 30 mg level, researchers saw only a 20% median reduction.
- Stoke had approximately $252.2 million in cash, cash equivalents, marketable securities, and restricted cash, which is anticipated to fund operations into 2025.
- STOK reported a widened net loss for Q3 of $(26.1) million, or $(0.66) per share, versus $(22.6) million, or $(0.61) per share a year-ago.
- Price Action: STOK shares are down 26.10% at $9.23 on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
